Abstract 1866
Background
Inhibition of PD-1 has demonstrated improved survival as single agent in refractory EGA compared to placebo. In 1st line HER2 negative EGA combination regimens of PD-1 inhibitors (i) with chemotherapy or CTLA4i are currently investigated. Since a survival benefit could not be shown for the addition of pertuzumab, the TOGA regimen with platinum, fluoropyrimidine and trastuzumab remains the standard of care in 1st line HER2+ EGA. Combination regimens with PD-1i +/- CTLA4i have not yet been evaluated in HER2+ EGA. Thus, the INTEGA trial will evaluate two trastuzumab and PD-1i based combinations to determine the best regimen to challenge the TOGA regimen in a phase 3 trial.
Trial design
INTEGA is a randomized exploratory phase II investigator initiated trial by the AIO esophagogastric working group with two experimental arms. Patients (pts) with previously untreated (for metastatic disease) HER2 + (IHC3+ or 2+/ISH+) EGA will be randomized to receive trastuzumab and nivolumab in combination with either mFOLFOX6 or ipilimumab (3mg/kg every 3 weeks). Treatment with nivolumab is limited to a maximum of 12 months, ipilimumab to 4 applications. Primary endpoint is 12month overall survival rate, which should be increased from 55% (TOGA regimen) to 70% in each arm. Based on a type I error of 5% and 80% power 41 pts per arm are required and with a 15% drop out rate overall 97 pts will be randomized. An early stopping rule will be applied in case of an increase in toxicity after the first 15 pts received at least two months of treatment. The trial is flanked by a large translational program including immunoprofiling to determine and correlate the respective immune response signatures with clonal dynamics. Recruitment has started in March 2018. Overall 40 German sites are planned. Conclusion: The INTEGA trial will determine the feasibility and efficacy of trastuzumab and nivolumab in combination with either mFOLFOX6 or ipilimumab in 1st line HER2+ EGA. The translational research program will shed light on the potential mode of action of these novel combinations.
Clinical trial identification
NCT03409848.
Legal entity responsible for the study
AIO-Studien-gGmbH.
Funding
BMS.
Editorial Acknowledgement
Disclosure
E. Goekkurt: Advisory board: Sanofi, Merck, BMS, MSD, Servier, Sirtex, Pfizer, Lilly; Speakers fees: Servier, MSD, BMS. M. Binder: Travel expanses: BMS, Hexal; Advisory board: Roche, BMS, MSD, Hexal, Takeda, Celgene, AbbVie; Speakers fees: Chugai, Roche, BMS, Janssen-Cilag, Hexal, Sanofi, Celgene, AstraZeneca. S. Lorenzen: Advisory board: Sanofi, Merck, BMS, MSD, Servier, Lilly, Roche; Speakers fees: Servier, Roche, BMS, Lilly. P.C. Thuss-Patience: Advisory board: Merck, Roche, Lilly, Pfizer, MSD, BMS, Nordic. S-E. Al-Batran: Advisory board, speakers fees: BMS. A. Hinke: Honoraria: Roche S. Hegewisch-Becker: Advisory board: Lilly, BMS, Merck. C. Bokemeyer: Research funding: German Cancer Aid, Sanofi, Roche, Merck, GBA Innovationfond, BMS; Honoraria: Merck, Sanofi, Roche, Bayer, BMS, Servier, AstraZeneca; Advisory board: Lilly/ImClone, Mundipharma, Hexal, Bayer Schering, Sanofi, Merck. Travel, accommodations, expenses: Merck Serono, Sanofi, Pfizer, BMS. A. Stein: Research funding: German Cancer Aid, Sanofi, Roche, Merck, GBA Innovationfond, BMS; Advisory board: Sanofi, Amgen, Merck, Roche, BMS, MSD, Servier, Sirtex; Speakers fees: Sanofi, Merck, Roche, Servier, Bayer, Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
4867 - The Combination of TAS-102 and Bevacizumab as the third line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study)
Presenter: Hirohiko Kamiyama
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1436 - Safety run-in evaluation of the phase I trial of trifluridine/tipiracil (FTD/TPI) in combination with oxaliplatin and a monoclonal antibody (bevacizumab or nivolumab) in patients (pts) with metastatic colorectal cancer (mCRC)
Presenter: Aitana Calvo Ferrandiz
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3551 - A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study
Presenter: Mitsukuni Suenaga
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1904 - Sidedness of the Primary Tumor on the Effect of TAS-102 for Refractory metastatic colorectal cancer
Presenter: Shinya Ueda
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2350 - Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib
Presenter: Femke de Man
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1565 - A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial.
Presenter: Thomas Seufferlein
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2327 - Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer
Presenter: Masato Nakamura
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2645 - Aflibercept in combination with Irinotecan, fluorouracil and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal cancer (mCRC) patients : a phase II multicentric study.
Presenter: Alexandra Lapeyre-Prost
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1927 - Folfiri-Aflibercept vs Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice.
Presenter: Alessandro Ottaiano
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2453 - In the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?
Presenter: Elena Mata Velasco
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract